litlas
ログインアカウント作成

Douglas L. Arnold

1980–2026 年に発表

295
論文数
43,147
被引用数
112
h 指数
253
i10 指数

被引用数

Douglas L. Arnold の年別被引用数1973 年: 被引用 2 件1974 年: 被引用 3 件1978 年: 被引用 1 件1980 年: 被引用 1 件1981 年: 被引用 3 件1982 年: 被引用 1 件1983 年: 被引用 1 件1984 年: 被引用 3 件1985 年: 被引用 9 件1986 年: 被引用 13 件1987 年: 被引用 7 件1988 年: 被引用 15 件1989 年: 被引用 17 件1990 年: 被引用 23 件1991 年: 被引用 23 件1992 年: 被引用 23 件1993 年: 被引用 44 件1994 年: 被引用 46 件1995 年: 被引用 79 件1996 年: 被引用 59 件1997 年: 被引用 88 件1998 年: 被引用 129 件1999 年: 被引用 175 件2000 年: 被引用 187 件2001 年: 被引用 205 件2002 年: 被引用 203 件2003 年: 被引用 219 件2004 年: 被引用 187 件2005 年: 被引用 209 件2006 年: 被引用 199 件2007 年: 被引用 215 件2008 年: 被引用 229 件2009 年: 被引用 206 件2010 年: 被引用 232 件2011 年: 被引用 231 件2012 年: 被引用 232 件2013 年: 被引用 282 件2014 年: 被引用 316 件2015 年: 被引用 398 件2016 年: 被引用 352 件2017 年: 被引用 410 件2018 年: 被引用 459 件2019 年: 被引用 1,353 件2020 年: 被引用 1,561 件2021 年: 被引用 1,513 件2022 年: 被引用 1,337 件2023 年: 被引用 953 件2024 年: 被引用 1,614 件2025 年: 被引用 822 件2026 年: 被引用 21 件1975〜1977 年は被引用が無いため表示していません1979 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,386 件、この内訳の 22.5%イギリス: 引用元論文 1,372 件、この内訳の 9.1%ドイツ: 引用元論文 1,173 件、この内訳の 7.8%カナダ: 引用元論文 1,152 件、この内訳の 7.7%イタリア: 引用元論文 1,094 件、この内訳の 7.3%フランス: 引用元論文 608 件、この内訳の 4%スイス: 引用元論文 598 件、この内訳の 4%中国: 引用元論文 543 件、この内訳の 3.6%スペイン: 引用元論文 512 件、この内訳の 3.4%オランダ: 引用元論文 497 件、この内訳の 3.3%オーストラリア: 引用元論文 454 件、この内訳の 3%スウェーデン: 引用元論文 270 件、この内訳の 1.8%
0%22.5%その他 22.5%

機関

分野

  • Medicine67.8%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Neuroscience8.2%
  • Computer Science4.9%
  • Immunology and Microbiology4.1%
  • Engineering1%
  • その他2.7%

トピック

  • Multiple Sclerosis Research Studies15.2%
  • Peripheral Neuropathies and Disorders4.6%
  • Advanced MRI Techniques and Applications3.4%
  • Neuroinflammation and Neurodegeneration Mechanisms2.5%
  • Advanced Neuroimaging Techniques and Applications2.4%
  • Polyomavirus and related diseases2.1%
  • その他69.8%

共著者

全論文

検索で開く
  1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

    著者: Stephen L. Hauser, Amit Bar‐Or, Gıancarlo Comı, Gavin Giovannoni, Hans‐Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalbán, Kottil Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Jerry S. Wolinsky, Douglas L. Arnold, Gaëlle Klingelschmitt, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Peter Chin, Nicole Mairon, Hideki Garren, Ludwig Kappos - New England Journal of Medicine 2016 被引用: 1,961

  2. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

    著者: Ludwig Kappos, Jerry S. Wolinsky, Gavin Giovannoni, Douglas L. Arnold, Qing Wang, Corrado Bernasconi, Fabian Model, Harold Koendgen, Marianna Manfrini, Shibeshih Belachew, Stephen L. Hauser - JAMA Neurology 2020 被引用: 622

  3. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    著者: Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos, Douglas L. Arnold, Amit Bar‐Or, Giancarlo Comi, de Sèze, Gavin Giovannoni, Hans‐Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki Garren, Nicole Mairon, Peter Chin, Jerry S. Wolinsky - New England Journal of Medicine 2016 被引用: 1,856

  4. How patients with multiple sclerosis acquire disability

    著者: Fred Lublin, Dieter A. Häring, Habib Ganjgahi, Alex Ocampo, Farhad Hatami, Jelena Čuklina, Piet Aarden, Frank Dahlke, Douglas L. Arnold, Heinz Wiendl, Tanuja Chitnis, Thomas E. Nichols, Bernd C. Kieseier, Robert A Bermel - Brain 2022 被引用: 528

  5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    著者: Ludwig Kappos, Amit Bar‐Or, Bruce Cree, Robert J. Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L. Arnold, Sophie Arnould, Tatiana Scherz, Christian Wolf, Erik Wallström, Frank Dahlke, Anat Achiron, Lutz Achtnichts, Kadriye Ağan, Gülşen Akman‐Demir, Alison Allen, Jack P. Antel, Alfredo Rodríguez Antigüedad, Michelle Apperson, Angela Applebee, Guillermo Izquierdo Ayuso, Masayuki Baba, Ovidiu Băjenaru, Rodica Balasa, Belgin Petek Balcı, Michael Barnett, Ann Bass, V. Becker, Mihaela Bejinariu, Florian Then Bergh, Arnfin Bergmann, Evanthia Bernitsas, Achim Berthele, Virender Bhan, Felix Bischof, Randall J. Bjork, Gregg Blevins, Matthias Boehringer, Thomas Boerner, Robert Bonek, James D. Bowen, Allen C. Bowling, Alexey Boyко, Cavit Boz, Vera Bracknies, Stefan Braune, Vincenzo Brescia Morra, Bruno Brochet, Waldemar Brola, Paul Brownstone, M Brozman, Donald Brunet, Ioan Buraga, Margaret Burnett, Mathias Buttmann, Helmut Butzkueven, Jonathan Cahill, Jonathan Calkwood, William Camu, Mark Cascione, G. Castelnovo, Diego Centonze, João Cerqueira, Andrew Chan, Andrea Cimprichová, Stanley Cohan, Giancarlo Comi, Jill Ker Conway, Joanna A. Cooper, John R. Corboy, Jorge Correale, Brian Costell, David A. Cottrell, Patricia K. Coyle, Matthew Craner, Liying Cui, Luı́s Cunha, Anna Członkowska, Ana Silva, Joao de, de Sèze, Marc Debouverie, Jan Debruyne, D. Decoo, G. Defer, Tobias Derfuß, Norma Deri, Bhupesh Dihenia, Péter Diószeghy, Vladimír Donáth, Bénédicte Dubois, Martin Duddy, Pierre Duquette, Gilles Edan, Hüsnü Efendi, Stanton B. Elias, Peter Emrich, Bonaventura Casanova Estruch ほか 228 名 - The Lancet 2018 被引用: 925

  6. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

    著者: Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold, Timothy R. Vollmer, Jack P. Antel, Robert J. Fox, Amit Bar‐Or, Michael Panzara, Neena Sarkar, Sunil Agarwal, Annette Langer‐Gould, Craig H. Smith - New England Journal of Medicine 2008 被引用: 2,399

  7. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    著者: Ralf Gold, Ludwig Kappos, Douglas L. Arnold, Amit Bar‐Or, Gavin Giovannoni, Krzysztof Selmaj, Carlo Tornatore, Marianne T. Sweetser, Minhua Yang, Sarah Sheikh, Katherine Dawson - New England Journal of Medicine 2012 被引用: 1,703

  8. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data

    著者: Arman Eshaghi, Alexandra L. Young, P. A. Wijeratne, Ferrán Prados, Douglas L. Arnold, Sridar Narayanan, Charles R.G. Guttmann, Frederik Barkhof, Daniel C. Alexander, Alan J. Thompson, Declan Chard, Olga Ciccarelli - Nature Communications 2021 被引用: 255

  9. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

    著者: Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch, Amit Bar‐Or, Robert J. Fox, André Palma da Cunha Matta, Timothy J. Turner, Erik Wallström, Xinyan Zhang, Miroslav Mareš, Ф. А. Хабиров, Anthony Traboulsee, François Grand’Maison, François Jacques, Anthony Traboulsee, Michaela Týblová, Eva Meluzínová, Radek Ampapa, Martin Vališ, Pavel Hradilke, Miroslav Mareš, Pavel Štourač, Katrin Gross‐Paju, David Laplaud, Guillaume Mathey, Bernard M.J. Uitdehaag, Evgeny Evdoshenkoo, Е. В. Попова, Maria Zakharova, N. А. Totolyan, И. В. Литвиненко, Ф. А. Хабиров, С А Сиверцева, Viera Hančinová, Ema Kantorová, María Luisa Martínez Ginés, Xavier Montalbán, Sara Eichau Maduano, José Meca-Lallana, Lluís Ramió‐Torrentà, Tetyanna Nehrych, V.M. Pashkovskyy, Sergii Moskovko, O. I. Kalbus, Marta Khavunka, Volodymyr Pryshchepa, Alla Goloborodko, Daniel Wynn, William Honeycutt, Sibyl Wray, Brian Steingo, Christopher LaGanke, DeRen Huang, John M. Hemphill, Lawrence Goldstick, Derrick Robertson - The Lancet Neurology 2021 被引用: 192

  10. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

    著者: Xavier Montalbán, Douglas L. Arnold, Martin S. Weber, Ivan Staikov, Karolina Piasecka‐Stryczynska, Jonathan Willmer, Emily C. Martin, Fernando Dangond, Sana Syed, Jerry S. Wolinsky - New England Journal of Medicine 2019 被引用: 320

  11. Secondary Progressive Multiple Sclerosis

    著者: Bruce Cree, Douglas L. Arnold, Jeremy Chataway, Tanuja Chitnis, Robert J. Fox, Angela Pozo Ramajo, Niamh Murphy, Hans Lassmann - Neurology 2021 被引用: 252

  12. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

    著者: Colm Elliott, Jerry S. Wolinsky, Stephen L. Hauser, Ludwig Kappos, Frederik Barkhof, Corrado Bernasconi, Wei Wei, Shibeshih Belachew, Douglas L. Arnold - Multiple Sclerosis Journal 2018 被引用: 214

  13. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

    著者: Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Elizabeth Fisher, Vesna Brinar, Gavin Giovannoni, M. Stojanovic, Bella Ertik, Stephen Lake, David Margolin, Michael Panzara, D. A. S. Compston - The Lancet 2012 被引用: 1,198

  14. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

    著者: Colm Elliott, Shibeshih Belachew, Jerry S. Wolinsky, Stephen L. Hauser, Ludwig Kappos, Frederik Barkhof, Corrado Bernasconi, Julian Fecker, Fabian Model, Wei Wei, Douglas L. Arnold - Brain 2019 被引用: 215

  15. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

    著者: Alasdair Coles, Cary Twyman, Douglas L. Arnold, Jeffrey Cohen, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Elizabeth Fisher, Rupert Sandbrink, Stephen Lake, David Margolin, Pedro Oyuela, Michael Panzara, D. A. S. Compston - The Lancet 2012 被引用: 1,193

  16. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    著者: Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L. Arnold, Mark S. Freedman, Myla Goldman, Hans-Peter Hartung, Eva Havrdová, Douglas Jeffery, A Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, E Bartholomé, Marie D’hooghe, Massimo Pandolfo, Bart Van Wijmeersch, Virender Bhan, Gregg Blevins, Donald Brunet, Virginia Devonshire, Pierre Duquette, Mark S. Freedman, François Grand’Maison, François Jacques, Yves Lapierre, Liesly Lee, Sarah A. Morrow, Michael Yeung, Michal Dufek, Eva Havrdová, Petr Kaňovský, Ivana Štětkářová, Marika Talábová, Jette Lautrup Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, Finn Sellebjerg, Laura Airas, Irina Elovaara, Juha-Pekka Erälinna, Taneli Sarasoja, Abdullatif Al Khedr, David Brassat, Bruno Brochet, William Camu, Marc Debouverie, David Laplaud, Christine Lebrun‐Frénay, Jean Pelletier, Patrick Vermersch, Sandra Vukusi, Karl Baum, Achim Berthele, Juergen Faiss, Peter Flachenecker, Reinhard Hohlfeld, Markus Krumbholz, Christoph Lassek, Mathias Maeurer, Sven G. Meuth, Tjalf Ziemssen, Orla Hardiman, Christopher McGuigan, Anat Achiron, Dimitrios Karussis, Roberto Bergamaschi, Vincenzo Brescia Morra, Giancarlo Comi, Salvatore Cottone, Luigi M.E. Grimaldi, Giovanni Luigi Mancardi, Luca Massacesi, Ugo Nocentini, Marco Salvetti, Elio Scarpini, Patrizia Sola, Gioacchino Tedeschi, María Trojano, Mauro Zaffaroni, Stephan Frequin, Raymond Hupperts, Joep Killestein, Hans M. Schrijver, Ronald Van Dijl, Erik van Munster, Maciej Czarnecki, Wiesław Drozdowski, Waldemar Fryze, Hanka Hertmanowska, Jan Ilkowski, Anna Kamińska, Gabriela Kłodowska-Duda ほか 90 名 - The Lancet Neurology 2018 被引用: 337

  17. Five years of ocrelizumab in relapsing multiple sclerosis

    著者: Stephen L. Hauser, Ludwig Kappos, Douglas L. Arnold, Amit Bar‐Or, Bruno Brochet, Robert T. Naismith, Anthony Traboulsee, Jerry S. Wolinsky, Shibeshih Belachew, Harold Koendgen, Victoria Levesque, Marianna Manfrini, Fabian Model, Stanislas Hubeaux, Lahar Mehta, Xavier Montalbán - Neurology 2020 被引用: 158

  18. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

    著者: Diego Cadavid, Michelle Mellion, Raymond Hupperts, Keith R. Edwards, Peter A. Calabresi, Jelena Drulović, Gavin Giovannoni, Hans‐Peter Hartung, Douglas L. Arnold, Elizabeth Fisher, Richard A. Rudick, Sha Mi, Yi Chai, Jie Li, Yiwei Zhang, Wenting Cheng, Lei Xu, Bing Zhu, Susan M Green, Ih Chang, Aaron Deykin, Sarah Sheikh, Eduardo Agüera, Abdullatif Al Khedr, Radek Ampapa, Rafael Arroyo, Martin Belkin, Robert Bonek, Alexey Boyко, Ruggero Capra, Diego Centonze, Pierre Clavelou, Marc Debouverie, Jelena Drulović, Keith R. Edwards, Nikos Evangelou, E. P. Evdoshenko, Óscar Fernández, Victoria Fernández Sánchez, Mark Freedman, Steven Freedman, Waldemar Fryze, Antonio Garcı́a-Merino, Mira Gavric-Kezic, Angel Ghezzi, Olivier Gout, Luigi M.E. Grimaldi, Barry Hendin, Hanka Hertmanowska, Rogier Hintzen, Pavel Hradílek, Raymond Hupperts, Jan Ilkowski, Evelina Ivashinenkova, Guillermo Izquierdo, François Jacques, Gábor Jakab, Ф. А. Хабиров, Gabriela Kłodowska-Duda, S. Komoly, Smiljana Kostić, Ivana Kovářová, Marcelo Kremenchuzky, Christopher LaGanke, Yves Lapierre, Maciej Maciejowski, Francois Grand’ Maison, Girolama Alessandra Marfia, Sergio Martínez‐Yélamos, Eva Meluzínová, Xavier Montalbán, Ronald S. Murray, Robert T. Naismith, Scott D. Newsome, Viet‐Anh Nguyen, Delia Oreja, Gabriel Pardo, Elena S. Pasechnik, Francesco Patti, Andrzej Potemkowski, С. В. Прокопенко, Peiqing Qian, Alfredo Rodríguez Antigüedad, Howard Rossman, Csilla Rózsa, Fernando Sánchez López, Krzysztof Selmaj, Eli Silber, Adam Stępień, Anna Stepniewska, Maciej Świat, Gordana Tončev, Ayman Tourbah, Tatyana Trushnikova, Antonio Uccelli, Marta Vachová, Martin Vališ, László Vécsei, Sandrine Wiertlewski, Mauro Zaffaroni ほか 1 名 - The Lancet Neurology 2019 被引用: 185

  19. Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes

    著者: Patrick Waters, Giulia Fadda, Mark Woodhall, Julia O’Mahony, Robert A. Brown, Denise Castro, Giulia Longoni, Sarosh R. Irani, Bo Sun, E. Ann Yeh, Ruth Ann Marrie, Douglas L. Arnold, Brenda Banwell, Amit Bar‐Or, for the Canadian Pediatric Demyelinating Disease Network - JAMA Neurology 2019 被引用: 331

  20. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

    著者: Gıancarlo Comı, Ludwig Kappos, Krzysztof Selmaj, Amit Bar‐Or, Douglas L. Arnold, Lawrence Steinman, Hans‐Peter Hartung, Xavier Montalbán, Eva Havrdová, Bruce Cree, James K. Sheffield, Neil Minton, Kartik Raghupathi, Ning Ding, Jeffrey A. Cohen - The Lancet Neurology 2019 被引用: 286

  21. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

    著者: Tanuja Chitnis, Douglas L. Arnold, Brenda Banwell, Wolfgang Brück, Angelo Ghezzi, Gavin Giovannoni, Benjamin Greenberg, Lauren Krupp, Kevin Rostásy, Marc Tardieu, Emmanuelle Waubant, Jerry S. Wolinsky, Amit Bar‐Or, Tracy Stites, Yu Chen, Norman Putzki, Martin Merschhemke, Jutta Gärtner - New England Journal of Medicine 2018 被引用: 326

  22. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

    著者: Jeffrey A. Cohen, Gıancarlo Comı, Krzysztof Selmaj, Amit Bar‐Or, Douglas L. Arnold, Lawrence Steinman, Hans‐Peter Hartung, Xavier Montalbán, Eva Havrdová, Bruce Cree, James K. Sheffield, Neil Minton, Kartik Raghupathi, Vivian Huang, Ludwig Kappos - The Lancet Neurology 2019 被引用: 279

  23. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis

    著者: Colm Elliott, David A. Rudko, Douglas L. Arnold, Dumitru Fetco, Ahmed M. Elkady, David Araújo, Bing Zhu, Arie Gafson, Zhe Tian, Shibeshih Belachew, Daniel P. Bradley, Elizabeth Fisher - Multiple Sclerosis Journal 2023 被引用: 62

  24. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

    著者: Harold Atkins, Marjorie A. Bowman, David Allan, Grizel Anstee, Douglas L. Arnold, Amit Bar‐Or, Isabelle Bence‐Bruckler, Paul Birch, Christopher Bredeson, Jacqueline Chen, Dean Fergusson, Mike Halpenny, Linda Hamelin, Lothar Huebsch, Brian Hutton, Pierre Laneuville, Yves Lapierre, Hyunwoo Lee, Lisa Martin, Sheryl McDiarmid, Paul O’Connor, Tim Ramsay, Mitchell Sabloff, Lisa A.S. Walker, Mark S. Freedman - The Lancet 2016 被引用: 322